Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <=60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

被引：0

作者：

Nazha, Aziz

Ravandi, Farhad

Kantarjian, Hagop M.

Huang, Xuelin ^{[2
]}

Choi, Sangbum ^{[2
]}

Garcia-Manero, Guillermo

Jabbour, Elias J.

Borthakur, Gautam

Kadia, Tapan M.

Konopleva, Marina ^{[1
]}

Cortes, Jorge E.

Ferrajoli, Alessandra

Kornblau, Steven M.

Andreeff, Michael ^{[1
]}

Estrov, Zeev

Daver, Naval G.

Pemmaraju, Naveen

Du, Mm

Brandt, Mark

Faderl, Stefan

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Mol Hematol & Therapy, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.43.43

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
Nazha, Aziz
Kantarjian, Hagop
Ravandi, Farhad
Huang, Xuelin
Choi, Sangbum
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan
Konopleva, Marina
Cortes, Jorge
Ferrajoli, Alessandra
Kornblau, Steve
Daver, Naval
Pemmaraju, Naveen
Andreeff, Michael
Estrov, Zeev
Du, Min
Brandt, Mark
Faderl, Stefan
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (11) : 961 - 966
[2] Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)
Nazha, Aziz
Ravandi, Farhad
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan
Konopleva, Marina
Cortes, Jorge E.
Ferrajoli, Alessandra
Kornblau, Steven M.
Andreeff, Michael
Du, Min
Brandt, Mark
Faderl, Stefan
[J]. BLOOD, 2011, 118 (21) : 674 - 674
[3] Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)
Nazha, Aziz
Kantarjian, Hagop M.
Ravandi, Farhad
Huang Xuelin
Choi, Sangbum
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautarn
Kadia, Tapan M.
Konopleva, Marina
Cortes, Jorge E.
Ferrajoli, Alessandra
Kornblau, Steven M.
Andreeff, Michael
Du, Min
Brandt, Mark
Faderl, Stefan H.
[J]. BLOOD, 2013, 122 (21)
[4] Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML).
Mathisen, Michael
Kantarjian, Hagop
Faderl, Stefan
Garcia-Manero, Guillermo
Ravandi, Farhad
Kadia, Tapan M.
Daver, Naval Guastad
O'Brien, Susan Mary
Dorkhom, Stephan Joseph
Pierce, Sherry
Lira, Cynthia
Cortes, Jorge E.
Jabbour, Elias
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[5] Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥ 60 years with newly diagnosed acute myeloid leukemia (AML)
Faderl, S
Ravandi, F
Ferrajoli, A
Garcia-Manero, G
Estrov, Z
Thomas, DA
O'Brien, S
Verstovsek, S
Wierda, W
Cortes, J
Giles, FJ
Kwari, M
Jarmon, R
Kantarjian, HM
[J]. BLOOD, 2005, 106 (11) : 786A - 786A
[6] Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML)
Jain, Nitin
Ravandi, Farhad
Garcia-Manero, Guillermo
Borthakur, Gautam
Kadia, Tapan M.
Jabbour, Elias J.
Pemmaraju, Naveen
Daver, Naval
DiNardo, Courtney D.
Konopleva, Marina
Alvarado, Yesid
Takahashi, Koichi
Benton, Christopher B.
Pike, Allison
Pierce, Sherry
Cortes, Jorge E.
Kantarjian, Hagop M.
[J]. BLOOD, 2016, 128 (22)
[7] A Randomized Phase 2 Study of Idarubicin and Cytarabine With Clofarabine or Fludarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Jabbour, Elias
Short, Nicholas J.
Ravandi, Farhad
Huang, Xuelin
Xiao, Lianchun
Garcia-Manero, Guillermo
Plunkett, William
Gandhi, Varsha
Sasaki, Koji
Pemmaraju, Naveen
Daver, Naval G.
Borthakur, Gautam
Jain, Nitin
Konopleva, Marina
Estrov, Zeev
Kadia, Tapan M.
Wierda, William G.
DiNardo, Courtney D.
Brandt, Mark
O'Brien, Susan M.
Cortes, Jorge E.
Kantarjian, Hagop
[J]. CANCER, 2017, 123 (22) : 4430 - 4439
[8] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Naqvi, Kiran
Ravandi, Farhad
Kantarjian, Hagop
Borthakur, Gautam
Ferrajoli, Alessandra
Thomas, Deborah A.
Koller, Charles Asa
Konopleva, Marina
Byrd, Anna
Kwari, Monica
Faderl, Stefan
[J]. BLOOD, 2010, 116 (21) : 464 - 465
[9] Results of a Randomized Phase 2 Study of Clofarabine Plus Cytarabine (CA) Vs Clofarabine Plus Idarubicin (CI) Vs Clofarabine, Idarubicin, Plus Cytarabine (CIA) as Salvage Therapy in Acute Myeloid Leukemia (AML).
Faderl, Stefan
Borthakur, Gautam
Ravandi, Farhad
Huang, Xuelin
Beran, Miloslav
Ferrajoli, Alessandra
Koller, Charles A.
Thomas, Deborah A.
Verstovsek, Srdan
Kwari, Monica
Kantarjian, Hagop M.
[J]. BLOOD, 2008, 112 (11) : 354 - 355
[10] Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML)
Mathisen, Michael S.
Kantarjian, Hagop M.
Ravandi, Farhad
Pemmaraju, Naveen
Garcia-Manero, Guillermo
Cortes, Jorge E.
O'Brien, Susan
Quintas-Cardama, Alfonso
Ghanem, Hady
Daver, Naval G.
Pierce, Sherry A.
Lira, Cynthia
Faderl, Stefan
Jabbour, Elias
[J]. BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients &lt;=60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <=60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)